TABLE 6.

Ratio of C_max of CEP in humans/IC₅₀ of CEP for anti-SARS-COV-2 in vitro.

N.O.	Drug	Usage	Dosage (mg)	Cmax in humans (ng/mL)	IC50 in vitro (ng/mL)	Cmax/IC50 ratio	References
A	CEP	p.o.	10	0.53 ± 0.06	28.51	0.02	Kohtaro et al. (1989), Moro et al. (1989), Hao et al. (2010), He et al. (2021)
B			30	2.35 ± 0.48		0.08
C			60	3.46 ± 0.27		0.12
D			120	6.78 ± 1.11		0.24
E		i.v., treatment in 5 min	25	187 ± 14		6.56
F			50	433 ± 25		15.19
G			100	1,464 ± 364		51.35
H		i.v., treatment in 5 min, for 7 days	100	Cmax: 196.3 ± 27.50		6.89
				Cmin: 34.0 ± 2.32		1.19
I		i.v., treatment in 60 min	50	135.9 ± 66.9		4.77